Alkermes plc (8AK) - Net Assets
Based on the latest financial reports, Alkermes plc (8AK) has net assets worth €1.75 Billion EUR (≈ $2.05 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.26 Billion ≈ $4.98 Billion USD) and total liabilities (€2.51 Billion ≈ $2.93 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 8AK intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.75 Billion |
| % of Total Assets | 41.13% |
| Annual Growth Rate | 4.56% |
| 5-Year Change | 63.52% |
| 10-Year Change | 30.24% |
| Growth Volatility | 14.21 |
Alkermes plc - Net Assets Trend (2013–2025)
This chart illustrates how Alkermes plc's net assets have evolved over time, based on quarterly financial data. See 8AK defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Alkermes plc (2013–2025)
The table below shows the annual net assets of Alkermes plc from 2013 to 2025. For live valuation and market cap data, see Alkermes plc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.82 Billion ≈ $2.13 Billion |
+24.19% |
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
+21.81% |
| 2023-12-31 | €1.20 Billion ≈ $1.41 Billion |
+15.23% |
| 2022-12-31 | €1.04 Billion ≈ $1.22 Billion |
-6.19% |
| 2021-12-31 | €1.11 Billion ≈ $1.30 Billion |
-5.01% |
| 2018-12-31 | €1.17 Billion ≈ $1.37 Billion |
-2.62% |
| 2017-12-31 | €1.20 Billion ≈ $1.41 Billion |
-0.55% |
| 2016-12-31 | €1.21 Billion ≈ $1.41 Billion |
-7.97% |
| 2015-12-31 | €1.31 Billion ≈ $1.54 Billion |
-5.91% |
| 2014-12-31 | €1.40 Billion ≈ $1.63 Billion |
+31.14% |
| 2013-12-31 | €1.07 Billion ≈ $1.25 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Alkermes plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25252000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.55 Billion | 140.39% |
| Total Equity | €1.82 Billion | 100.00% |
Alkermes plc Competitors by Market Cap
The table below lists competitors of Alkermes plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WG Tech JiangXi Co Ltd
SHG:603773
|
$4.97 Billion |
|
Shandong Xinchao Energy Co Ltd
SHG:600777
|
$4.97 Billion |
|
Shenzhen Zhongjin Lingnan Nonfemet Co Ltd
SHE:000060
|
$4.97 Billion |
|
Pampa Energia SA
BA:PAMP
|
$4.97 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
$4.96 Billion |
|
Meritage Corporation
NYSE:MTH
|
$4.96 Billion |
|
Scout24 AG
XETRA:G24
|
$4.96 Billion |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
$4.96 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alkermes plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,464,977,000 to 1,819,295,000, a change of 354,318,000 (24.2%).
- Net income of 241,664,000 contributed positively to equity growth.
- Other factors increased equity by 112,654,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €241.66 Million | +13.28% |
| Other Changes | €112.65 Million | +6.19% |
| Total Change | €- | 24.19% |
Book Value vs Market Value Analysis
This analysis compares Alkermes plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.52x to 3.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €6.87 | €37.92 | x |
| 2022-12-31 | €6.35 | €37.92 | x |
| 2023-12-31 | €7.20 | €37.92 | x |
| 2024-12-31 | €9.03 | €37.92 | x |
| 2025-12-31 | €10.99 | €37.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alkermes plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.28%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.37%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.37x
- Recent ROE (13.28%) is above the historical average (-1.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 1.94% | 3.46% | 0.38x | 1.48x | €-85.87 Million |
| 2014 | -2.15% | -4.86% | 0.32x | 1.37x | €-169.74 Million |
| 2015 | -17.28% | -36.15% | 0.34x | 1.41x | €-358.59 Million |
| 2016 | -17.23% | -27.95% | 0.43x | 1.43x | €-329.39 Million |
| 2017 | -13.13% | -17.48% | 0.50x | 1.49x | €-278.23 Million |
| 2018 | -11.89% | -12.73% | 0.60x | 1.56x | €-256.44 Million |
| 2021 | -4.33% | -4.10% | 0.58x | 1.82x | €-159.43 Million |
| 2022 | -15.16% | -14.24% | 0.57x | 1.88x | €-262.64 Million |
| 2023 | 29.58% | 21.39% | 0.78x | 1.78x | €235.49 Million |
| 2024 | 25.06% | 23.57% | 0.76x | 1.40x | €220.57 Million |
| 2025 | 13.28% | 16.37% | 0.59x | 1.37x | €59.73 Million |
Industry Comparison
This section compares Alkermes plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,888,924,775
- Average return on equity (ROE) among peers: -44.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alkermes plc (8AK) | €1.75 Billion | 1.94% | 1.43x | $4.96 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $61.84 Billion | 5.45% | 0.94x | $1.13 Billion |
| PEPTONIC MEDICAL (28L) | $47.09 Million | -78.27% | 0.82x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.55 Billion | 13.15% | 0.55x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $216.42 Million | -22.23% | 0.32x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-9.91 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $17.35 Million | -23.30% | 0.22x | $13.93 Million |
| EQL PHARMA AB (7JK) | $221.03 Million | 19.51% | 2.66x | $78.37 Million |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more